NICE publishes final recommendation for Almirall's ILUMETRI®▼ (Tildrakizumab), as a cost-effective option for adults with moderate-to-severe plaque psoriasis

Dermatologists in the UK now have an additional biologic treatment option and suitable patients can be considered for treatment with ILUMETRI ® (Tildrakizumab) Tildrakizumab is a high-affinity humanized monoclonal antibody that inhibits the p19 subunit of IL-23 1 , that has demonstrated lasting efficacy and safety through 3 years according to the positive results of a pooled analysis 2 of two phase III clinical trials Tildrakizumab was approved by the European Commission in September 2018, is already available in Germany and is due to be marketed in all EU Member states ILUMETRI ® received a provisional approval from NICE on March 8 th 2019

The release as fetched from its publisher. almirall.com ↗